Cysteamine bitartrate delayed-release capsules: Additional Phase II/III data

Data from the open-label, crossover second part of the French Phase II/III CYST-HD trial in 96 HD patients showed that RP103 for 36 months slowed the rate of change in the TMS score component of the U...